E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis

Blood

Volumn 120, Issue 4, 2012, Pages 822-832

  Wolyniec, Kamil ^a,b   Shortt, Jake ^a,c   De Stanchina, Elisa ^d   Levav Cohen, Yaara ^e   Alsheich Bartok, Osnat ^e   Louria Hayon, Igal ^e,l   Corneille, Vincent ^a,b   Kumar, Beena ^f   Woods, Simone J ^a,b   Opat, Stephen ^c   Johnstone, Ricky W ^a,b   Scott, Clare L ^b,g   Segal, David ^g   Pandolfi, Pier Paolo ^h   Fox, Stephen ^a,b   Strasser, Andreas ^b,g   Jiang, Yong Hui ⁱ   Lowe, Scott W ^d   Haupt, Sue ^a,b   Haupt, Ygal ^a,b,j,k  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e HEBREW UNIVERSITY   (Israel)

^f Southern Health   (Australia)

^g WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k MONASH UNIVERSITY   (Australia)

^l MOUNT SINAI HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

E6AP UBIQUITIN LIGASE; HISTONE H3; MYC PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P16; PROTEIN P21; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER INHIBITION; CELL AGING; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84864495265     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-387647     Document Type: Article

References (52)

1. Potts BC, Albitar MX, Anderson KC, et al. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011;11(3):254-284.
2. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22(2):304-311. (Pubitemid 38725184)
3. Casté ra L, Sabbagh A, Dehainault C, et al. MDM2 as a modifier gene in retinoblastoma. J Natl Cancer Inst. 2010;102(23):1805-1808.
4. Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993;53(10 Suppl):2231-2234. (Pubitemid 23156805)
5. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358(6381):80-83.
6. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci U S A. 2001;98(3):1218-1223. (Pubitemid 32121213)
7. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129-1136. (Pubitemid 120035062)
8. Howley PM. Warts, cancer and ubiquitylation: lessons from the papillomaviruses. Trans Am Clin Climatol Assoc. 2006;117:113-126; discussion 126-117.
9. Matentzoglu K, Scheffner M. Ubiquitin ligase E6-AP and its role in human disease. Biochem Soc Trans. 2008;36(Pt 5):797-801.
10. Beaudenon S, Huibregtse JM. HPV E6, E6AP and cervical cancer. BMC Biochem. 2008;9(Suppl 1):S4.
11. Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, et al. E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ. 2009;16(8):1156-1166.
12. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93(10):3167-3215. (Pubitemid 29220886)
13. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet. 1998;20(3):266-272. (Pubitemid 28507671)
14. Wang ZG, Delva L, Gaboli M, et al. Role of PML in cell growth and the retinoic acid pathway. Science. 1998;279(5356):1547-1551. (Pubitemid 28217080)
15. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 2006;441(7092):523-527. (Pubitemid 44050155)
16. Gurrieri C, Capodieci P, Bernardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004;96(4):269-279. (Pubitemid 38256272)
17. Gurrieri C, Nafa K, Merghoub T, et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood. 2004;103(6):2358-2362. (Pubitemid 38326258)
18. Bernardi R, Papa A, Pandolfi PP. Regulation of apoptosis by PML and the PML-NBs. Oncogene. 2008;27(48):6299-6312.
19. Bourdeau V, Baudry D, Ferbeyre G. PML links aberrant cytokine signaling and oncogenic stress to cellular senescence. Front Biosci. 2009;14:475-485.
20. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 2000;14(16):2015-2027. (Pubitemid 30637352)
21. Vernier M, Bourdeau V, Gaumont-Leclerc MF, et al. Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev. 2011;25(1):41-50.
22. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10(1):51-57.
23. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer. 2011;11(7):503-511.
24. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev. 2010;24(22):2463-2479.
25. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046):533-538. (Pubitemid 16173038)
26. Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell. 1986;47(1):11-18. (Pubitemid 17181528)
27. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436(7052):807- 811. (Pubitemid 41160633)
28. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999;13(20):2670-2677. (Pubitemid 29508554)
29. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
30. Herold MJ, van den Brandt J, Seibler J, Reichardt HM. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc Natl Acad Sci U S A. 2008;105(47):18507-18512.
31. Wolyniec K, Wotton S, Kilbey A, et al. RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene. 2009;28(27):2502-2512.
32. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167(2):353-371. (Pubitemid 18073641)
33. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990;348(6299):331-333. (Pubitemid 120029100)
34. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci U S A. 2004;101(16):6164-6169. (Pubitemid 38520545)
35. Frenzel A, Labi V, Chmelewskij W, et al. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. Blood. 2010;115(5):995-1005.
36. Michalak EM, Jansen ES, Happo L, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 2009;16(5):684-696.
37. Langdon WY, Harris AW, Cory S. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy. Oncogene Res. 1988;3(3):271-279. (Pubitemid 19092752)
38. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 2003;22(6):1442-1450. (Pubitemid 36362707)
39. Post SM, Quintas-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene. 2010;29(9):1260-1269.
40. Reimann M, Lee S, Loddenkemper C, et al. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell. 2010;17(3):262-272.
41. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656-660. (Pubitemid 46232886)
42. Rakhra K, Bachireddy P, Zabuawala T, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell. 2010;18(5):485-498.
43. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol. 2009;219(1):3-15.
44. Reineke EL, Kao HY. PML: An emerging tumor suppressor and a target with therapeutic potential. Cancer Ther. 2009;7(A):219-226.
45. Happo L, Cragg MS, Phipson B, et al. Maximal killing of lymphoma cells by DNA damageinducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood. 2010;116(24):5256-5267.
46. Hubackova S, Novakova Z, Krejcikova K, et al. Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle. 2010;9(15):3085-3099.
47. Adams PD. Remodeling of chromatin structure in senescent cells and its potential impact on tumor suppression and aging. Gene. 2007;397(1-2):84-93. (Pubitemid 46992697)
48. Ye X, Zerlanko B, Kennedy A, Banumathy G, Zhang R, Adams PD. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell. 2007;27(2):183-196. (Pubitemid 47058300)
49. Zhang R, Poustovoitov MV, Ye X, et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell. 2005;8(1):19-30. (Pubitemid 40058002)
50. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003;113(6):703-716. (Pubitemid 36724935)
51. Scaglioni PP, Yung TM, Cai LF, et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell. 2006;126(2):269-283. (Pubitemid 44092959)
52. Yang Q, Deng X, Lu B, et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010;18(3):258-267.